PDCD1 and breast carcinoma: Furthermore, the ISPY 2 Trial data nominated ENPP1 as a potential companion diagnostic biomarker: ENPP1-low breast cancer patients are significantly more likely benefit from anti-PD-1 and PARPi therapies than their ENPP1-high counterparts.